文献速递精神分裂症与精神病性障碍

精神分裂症患者死亡率:相对风险与加重或减轻因素的系统综述与荟萃分析

Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors.
PubMed 文献 · World Psychiatry · 2022-01-01

该系统综述与荟萃分析纳入135项研究(精神分裂症N=4,536,447),发现精神分裂症患者全因死亡率较非精神分裂症对照组升高(RR=2.52,95%CI:2.38-2.68),首发精神分裂症相对一般人群风险最高(RR=7.43,95%CI:4.02-13.75),抗精神病药使用与全因死亡率降低相关(RR=0.71,95%CI:0.59-0.84)。

要点

  • 精神分裂症患者全因死亡率较任何非精神分裂症对照组升高(RR=2.52,95%CI:2.38-2.68)。
  • 抗精神病药使用与全因死亡率降低相关(RR=0.71,95%CI:0.59-0.84),SGA-LAIs效果最大(RR=0.39)。
  • 共病物质使用障碍增加全因死亡率(RR=1.62,95%CI:1.47-1.80)。

核心结论

  • 精神分裂症患者全因死亡率较非精神分裂症对照组升高(RR=2.52,95%CI:2.38-2.68,n=79)。
  • 首发精神分裂症相对一般人群全因死亡率风险最高(RR=7.43,95%CI:4.02-13.75,n=2)。
  • 抗精神病药使用与全因死亡率降低相关(RR=0.71,95%CI:0.59-0.84,n=11)。

研究设计与样本

  • 系统综述与随机效应荟萃分析,纳入1957至2021年发表的前瞻性与回顾性、全国性与针对性队列研究。
  • 共纳入135项研究,精神分裂症N=4,536,447,一般人群对照N=1,115,600,059,其他精神疾病对照N=3,827,955。
  • 主要结局为全因死亡率风险比(RR),关键次要结局为自杀与自然原因死亡率。

主要发现

  • 自杀或伤害中毒或未定非自然原因死亡率最高(RR=9.76-8.42),自然原因中肺炎次之(RR=7.00,95%CI:6.79-7.23)。
  • 全因死亡率随研究中位年份轻微但显著增加(beta=0.0009,95%CI:0.001-0.02,p=0.02)。
  • 发病期精神分裂症全因死亡率高于现患期(RR=3.52 vs. 2.86,p=0.009)。
  • 共病物质使用障碍增加全因死亡率(RR=1.62,95%CI:1.47-1.80,n=3)。
  • 第二代长效注射抗精神病药(SGA-LAIs)全因死亡率RR=0.39(95%CI:0.27-0.56,n=3),氯氮平RR=0.43(95%CI:0.34-0.55,n=3)。

关键数值与推荐

  • 全因死亡率:精神分裂症vs任何非精神分裂症对照组RR=2.52(95%CI:2.38-2.68,n=79)。
  • 首发精神分裂症vs一般人群全因死亡率RR=7.43(95%CI:4.02-13.75,n=2);发病期精神分裂症vs一般人群RR=3.52(95%CI:3.09-4.00,n=7)。
  • 抗精神病药vs无抗精神病药全因死亡率RR=0.71(95%CI:0.59-0.84,n=11);SGA-LAIs的RR=0.39(95%CI:0.27-0.56,n=3)。
  • 任何长效注射抗精神病药RR=0.47(95%CI:0.39-0.58,n=2);任何第二代抗精神病药RR=0.53(95%CI:0.44-0.63,n=4)。
  • 自杀或伤害中毒或未定非自然原因死亡率RR=9.76-8.42;肺炎RR=7.00(95%CI:6.79-7.23)。

临床怎么用

  • 针对共病物质滥用、长期维持抗精神病药治疗以及适当/更早使用SGA-LAIs和氯氮平可能缩小死亡率差距。
  • 抗精神病药对自然原因死亡率也具有保护作用,但第一代抗精神病药(FGAs)在发病期精神分裂症中与自杀和自然原因死亡率增加相关。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

People with schizophrenia die 15-20 years prematurely. Understanding mortality risk and aggravating/attenuating factors is essential to reduce this gap. We conducted a systematic review and random-effects meta-analysis of prospective and retrospective, nationwide and targeted cohort studies assessing mortality risk in people with schizophrenia versus the general population or groups matched for physical comorbidities or groups with different psychiatric disorders, also assessing moderators. Primary outcome was all-cause mortality risk ratio (RR); key secondary outcomes were mortality due to suicide and natural causes. Other secondary outcomes included any other specific-cause mortality. Publication bias, subgroup and meta-regression analyses, and quality assessment (Newcastle-Ottawa Scale) were conducted. Across 135 studies spanning from 1957 to 2021 (schizophrenia: N=4,536,447; general population controls: N=1,115,600,059; other psychiatric illness controls: N=3,827,955), all-cause mortality was increased in people with schizophrenia versus any non-schizophrenia control group (RR=2.52, 95% CI: 2.38-2.68, n=79), with the largest risk in first-episode (RR=7.43, 95% CI: 4.02-13.75, n=2) and incident (i.e., earlier-phase) schizophrenia (RR=3.52, 95% CI: 3.09-4.00, n=7) versus the general population. Specific-cause mortality was highest for suicide or injury-poisoning or undetermined non-natural cause (RR=9.76-8.42), followed by pneumonia among natural causes (RR=7.00, 95% CI: 6.79-7.23), decreasing through infectious or endocrine or respiratory or urogenital or diabetes causes (RR=3 to 4), to alcohol or gastrointestinal or renal or nervous system or cardio-cerebrovascular or all natural causes (RR=2 to 3), and liver or cerebrovascular, or breast or colon or pancreas or any cancer causes (RR=1.33 to 1.96). All-cause mortality increased slightly but significantly with median study year (beta=0.0009, 95% CI: 0.001-0.02, p=0.02). Individuals with schizophrenia <40 years of age had increased all-cause and suicide-related mortality compared to those ≥40 years old, and a higher percentage of females increased suicide-related mortality risk in incident schizophrenia samples. All-cause mortality was higher in incident than prevalent schizophrenia (RR=3.52 vs. 2.86, p=0.009). Comorbid substance use disorder increased all-cause mortality (RR=1.62, 95% CI: 1.47-1.80, n=3). Antipsychotics were protective against all-cause mortality versus no antipsychotic use (RR=0.71, 95% CI: 0.59-0.84, n=11), with largest effects for second-generation long-acting injectable anti-psychotics (SGA-LAIs) (RR=0.39, 95% CI: 0.27-0.56, n=3), clozapine (RR=0.43, 95% CI: 0.34-0.55, n=3), any LAI (RR=0.47, 95% CI: 0.39-0.58, n=2), and any SGA (RR=0.53, 95% CI: 0.44-0.63, n=4). Antipsychotics were also protective against natural cause-related mortality, yet first-generation antipsychotics (FGAs) were associated with increased mortality due to suicide and natural cause in incident schizophrenia. Higher study quality and number of variables used to adjust the analyses moderated larger natural-cause mortality risk, and more recent study year moderated larger protective effects of antipsychotics. These results indicate that the excess mortality in schizophrenia is associated with several modifiable factors. Targeting comorbid substance abuse, long-term maintenance antipsychotic treatment and appropriate/earlier use of SGA-LAIs and clozapine could reduce this mortality gap.

来源:World Psychiatry,查看原文。版权归原作者所有。

引用

  1. Correll CU, Solmi M, Croatto G, et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 2022. PMID: 35524619. doi:10.1002/wps.20994

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。